Bayer announced a 2026 Pharmaceuticals strategy focused on regulatory expansion, market penetration, high-value commercial products and an accelerated pipeline across oncology, cardiology, neurology and immunology.
Healthcare & Life Sciences · Germany
Previously: Bayer stated that artificial intelligence had become a Supervisory Board priority and that the company was increasingly using AI across the business to optimize processes, improve efficiency and accelerate innovation.
Read maintained: 2026-10-07